EC grants marketing authorisation for Sanofi and Regeneron ’s Dupixent for AD

The European Commission (EC) has granted marketing authorisation for Sanofi and Regeneron Pharmaceuticals ’ Dupixent (dupilumab) to treat adults with moderate to severe atopic dermatitis (AD), a form of eczema.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news